Jiangsu Hengrui Medicine Co., Ltd. (SHA: 600276)
China
· Delayed Price · Currency is CNY 48.27
-1.92 (-3.83%)
Nov 22, 2024, 3:00 PM CST
Jiangsu Hengrui Medicine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 25,553 | 22,377 | 21,213 | 25,780 | 27,613 | 23,247 | Upgrade
|
| Other Revenue | 442.6 | 442.6 | 62.25 | 125.22 | 121.91 | 41.78 | Upgrade
|
| Revenue | 25,995 | 22,820 | 21,275 | 25,906 | 27,735 | 23,289 | Upgrade
|
| Revenue Growth (YoY) | 16.34% | 7.26% | -17.87% | -6.59% | 19.09% | 33.70% | Upgrade
|
| Cost of Revenue | 3,738 | 3,562 | 3,503 | 3,756 | 3,356 | 2,918 | Upgrade
|
| Gross Profit | 22,257 | 19,257 | 17,772 | 22,150 | 24,379 | 20,370 | Upgrade
|
| Selling, General & Admin | 10,893 | 9,994 | 9,654 | 12,244 | 12,869 | 10,766 | Upgrade
|
| Research & Development | 5,777 | 4,954 | 4,887 | 5,943 | 4,989 | 3,896 | Upgrade
|
| Other Operating Expenses | 133.04 | 149.03 | 145.32 | 201.81 | 239.35 | 188.57 | Upgrade
|
| Operating Expenses | 16,799 | 15,081 | 14,712 | 18,385 | 18,107 | 14,869 | Upgrade
|
| Operating Income | 5,459 | 4,176 | 3,060 | 3,765 | 6,272 | 5,501 | Upgrade
|
| Interest Expense | -4.47 | -5.9 | -6.49 | -4.71 | - | - | Upgrade
|
| Interest & Investment Income | 617.2 | 477.14 | 772.64 | 580.9 | 631.7 | 436.41 | Upgrade
|
| Currency Exchange Gain (Loss) | 7.9 | 7.9 | 93.19 | -22.42 | -101.97 | 15.96 | Upgrade
|
| Other Non Operating Income (Expenses) | 64.63 | 0.74 | -1.37 | -198.97 | -3.89 | -97.15 | Upgrade
|
| EBT Excluding Unusual Items | 6,144 | 4,656 | 3,918 | 4,119 | 6,798 | 5,857 | Upgrade
|
| Gain (Loss) on Sale of Investments | -81.97 | -107.41 | 76.5 | 36.23 | 16.5 | 37.53 | Upgrade
|
| Gain (Loss) on Sale of Assets | -7.8 | -3.05 | 4.23 | 1.64 | 2.98 | -0.43 | Upgrade
|
| Asset Writedown | -48.04 | -70 | -130 | - | -2.28 | - | Upgrade
|
| Other Unusual Items | -64.5 | 191.68 | 100.11 | 309.04 | 80.67 | 161.98 | Upgrade
|
| Pretax Income | 5,941 | 4,667 | 3,968 | 4,466 | 6,895 | 6,056 | Upgrade
|
| Income Tax Expense | 498.35 | 389.29 | 153.35 | -17.72 | 586.59 | 729.31 | Upgrade
|
| Earnings From Continuing Operations | 5,443 | 4,278 | 3,815 | 4,484 | 6,309 | 5,326 | Upgrade
|
| Minority Interest in Earnings | 5.11 | 24.62 | 91.23 | 46.19 | 19.49 | 1.58 | Upgrade
|
| Net Income | 5,448 | 4,302 | 3,906 | 4,530 | 6,328 | 5,328 | Upgrade
|
| Net Income to Common | 5,448 | 4,302 | 3,906 | 4,530 | 6,328 | 5,328 | Upgrade
|
| Net Income Growth | 29.51% | 10.14% | -13.77% | -28.41% | 18.78% | 31.05% | Upgrade
|
| Shares Outstanding (Basic) | 6,336 | 6,327 | 6,404 | 6,381 | 6,392 | 6,394 | Upgrade
|
| Shares Outstanding (Diluted) | 6,336 | 6,327 | 6,404 | 6,381 | 6,392 | 6,394 | Upgrade
|
| Shares Change (YoY) | -0.70% | -1.20% | 0.37% | -0.18% | -0.02% | 0.48% | Upgrade
|
| EPS (Basic) | 0.86 | 0.68 | 0.61 | 0.71 | 0.99 | 0.83 | Upgrade
|
| EPS (Diluted) | 0.86 | 0.68 | 0.61 | 0.71 | 0.99 | 0.83 | Upgrade
|
| EPS Growth | 30.42% | 11.48% | -14.08% | -28.28% | 18.80% | 30.43% | Upgrade
|
| Free Cash Flow | 6,282 | 6,160 | -726.91 | 2,554 | 2,878 | 3,255 | Upgrade
|
| Free Cash Flow Per Share | 0.99 | 0.97 | -0.11 | 0.40 | 0.45 | 0.51 | Upgrade
|
| Dividend Per Share | 0.200 | 0.200 | 0.160 | 0.160 | 0.167 | 0.160 | Upgrade
|
| Dividend Growth | 25.00% | 25.00% | 0% | -4.02% | 4.32% | 25.53% | Upgrade
|
| Gross Margin | 85.62% | 84.39% | 83.53% | 85.50% | 87.90% | 87.47% | Upgrade
|
| Operating Margin | 21.00% | 18.30% | 14.38% | 14.53% | 22.61% | 23.62% | Upgrade
|
| Profit Margin | 20.96% | 18.85% | 18.36% | 17.49% | 22.82% | 22.88% | Upgrade
|
| Free Cash Flow Margin | 24.17% | 26.99% | -3.42% | 9.86% | 10.38% | 13.98% | Upgrade
|
| EBITDA | 6,199 | 4,830 | 3,599 | 4,260 | 6,720 | 6,120 | Upgrade
|
| EBITDA Margin | 23.85% | 21.17% | 16.92% | 16.45% | 24.23% | 26.28% | Upgrade
|
| D&A For EBITDA | 740.95 | 654.45 | 539.12 | 495.59 | 448.39 | 618.52 | Upgrade
|
| EBIT | 5,459 | 4,176 | 3,060 | 3,765 | 6,272 | 5,501 | Upgrade
|
| EBIT Margin | 21.00% | 18.30% | 14.38% | 14.53% | 22.61% | 23.62% | Upgrade
|
| Effective Tax Rate | 8.39% | 8.34% | 3.86% | - | 8.51% | 12.04% | Upgrade
|
| Revenue as Reported | 25,995 | 22,820 | 21,275 | 25,906 | 27,735 | 23,289 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.